showed that circulating CD4+ T cells with a high expression of CCR6 (Th17.1 cells) have a higher propensity to be recruited to the CNS of people with MS and are preferentially retained in the circulation by natalizumab treatment.21 This evidence concerns the gene CD4 and myeloid sarcoma.